Details

OSMI-4-based PROTACs do not influence O-GlcNAc transferase and O-GlcNAcylation levels in cells
ID Bricelj, Aleša (Author), ID Smrdel, Lara (Author), ID Steinebach, Christian (Author), ID Sosič, Izidor (Author), ID Anderluh, Marko (Author), ID Gobec, Martina (Author)

.pdfPDF - Presentation file, Download (1,16 MB)
MD5: DF26BE48358D0CD18DBC9CA2AE200DE2
URLURL - Source URL, Visit https://pubs.rsc.org/en/content/articlelanding/2025/ra/d5ra02801a This link opens in a new window

Abstract
The O-GlcNAc transferase (OGT) inhibitors disclosed thus far are burdened with certain shortcomings. We have incorporated OSMI-4, a nanomolar OGT inhibitor, into PROTACs. The prepared chimeras failed to induce effective OGT degradation or influence O-GlcNAcylation levels in MM.1S cells.

Language:English
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2025
Number of pages:Str. 25717–25723
Numbering:Vol. 15, no. 31
PID:20.500.12556/RUL-171401 This link opens in a new window
UDC:615.4:54
ISSN on article:2046-2069
DOI:10.1039/D5RA02801A This link opens in a new window
COBISS.SI-ID:243315203 This link opens in a new window
Publication date in RUL:25.08.2025
Views:507
Downloads:161
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:RSC advances
Publisher:RSC Publishing
ISSN:2046-2069
COBISS.SI-ID:2513252 This link opens in a new window

Licences

License:CC BY 3.0, Creative Commons Attribution 3.0 Unported
Link:https://creativecommons.org/licenses/by/3.0/deed.en
Description:You are free to reproduce and redistribute the material in any medium or format. You are free to remix, transform, and build upon the material for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Secondary language

Language:Slovenian
Keywords:zaviralci O-GlcNAc transferaze, OSMI-4, nanomolarni zaviralec OGT, farmacevtska kemija

Projects

Funder:EC - European Commission
Funding programme:H2020
Project number:765581
Name:Multidisciplinary European Joint Doctorate in the Design and Development of Glyco Drugs
Acronym:PhD4GlycoDrug
Funder:EC - European Commission
Funding programme:COST Action - European Regional Development Fund
Project number:P1-0208
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin
Funder:EC - European Commission
Funding programme:COST Action - European Regional Development Fund
Project number:CA18103
Name:Innovation with Glycans: new frontiers from synthesis to new biological targets (INNOGLY)
Funder:EC - European Commission
Funding programme:COST Action - European Regional Development Fund
Project number:CA18132
Name:Functional Glyconanomaterials for the Development of Diagnostics and Targeted Therapeutic Probes

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back